Thanks for that Lombard, but I don't see this as evidence of their stellar work. In fact, I think it shows they lack transparency in delaings with shareholders because this further delay in approval for Bronchitol was not flagged to shareholders before today, yet PXS is now saying that the requirement for an oral hearing to get European approval was expected. If that was the case, why then were PXS still telling shareholders as recently as a week or so ago that a decision was expected before the end of 2010? Presumably, you knew they weren't delivering an oral presentation at the last EMU meeting for the year? pretty disappointing to be honest. Hopefully won't have the same impact as the missed primary endpoint for the US study. All we ask is for them to tell us what's going on, not to spin some nonsense after the fact.
PXS Price at posting:
$2.64 Sentiment: Hold Disclosure: Held
